Skip to main content

Table 3 Treatment-Emergent Adverse Eventsa Observed during the Extension Phase

From: Maintenance of effect of duloxetine in Chinese patients with pain due to osteoarthritis: 13-week open-label extension data

Adverse Event, n (%) DLX_DLX PLA_DLX
N = 166 N = 175
Patients with ≥1 TEAE 42 (25.3) 81 (46.3)
Dry mouth 3 (1.8) 15 (8.6)
Somnolence 4 (2.4) 10 (5.7)
Alanine aminotransferase increased 3 (1.8) 10 (5.7)
Nausea 5 (3.0) 8 (4.6)
Aspartate aminotransferase increased 1 (0.6) 8 (4.6)
Dizziness 3 (1.8) 7 (4.0)
Constipation 1 (0.6) 7 (4.0)
Weight decreased 0 4 (2.3)
  1. Abbreviations: DLX duloxetine, PLA placebo, TEAE treatment-emergent adverse event
  2. aTEAEs occurring at a rate ≥2% in either treatment group